返回 Agenda
Session 5, Track C: Innovations within Pharmacovigilance: Shaping the Future of Drug Safety
Session Chair(s)
Daniel Greco, PHARMD, MS, RPH
Associate Director of Patient Safety, Bristol-Myers Squibb Company, Canada
Nadia Latif, MS
Senior Manager, Pharmacovigilance, Ipsen Biopharmaceuticals Canada Inc., Canada
The session will explore automation opportunities within pharmacovigilance, leveraging existing and rapidly evolving technology. Attendees will gain insights into how technologies such as Artificial Intelligence (AI) can enhance drug safety processes, improving efficiency and reduce the risk of human errors. The discussion will cover various automation model and key factors in evaluating their suitability across different pharmacovigilance workflows. Additionally, a case study will illustrate the practical considerations and impact of integrating automation into existing practices / processes.
Learning Objective : At the conclusion of this session, participants should be able to:- Define “Artificial Intelligence” and the models of automation
- Demonstrate the potential to integrate automation and/or AI to pharmacovigilance systems and workflows
- Identify risks associated with the use of new technology
Speaker(s)
Indy Ahluwalia
Senior Managing Consultant, ELIQUENT Life Sciences, United Kingdom
Navigating the Promises and Pitfalls of AI in Pharmacovigilance
Brian Dreyfus, MPH
Senior Director, Bristol-Myers Squibb Company, United States
Understanding Case Reporting Transmission Networks in Drug Safety: The Impact of Replication
Ricardo Pasquel Cook, MD
Safety Team Lead, Pfizer Inc., Canada
The Effectiveness of Online Reporting Portals in Comparison to Traditional Reporting Methods